[
    [
        {
            "time": "2021-Q3",
            "original_text": "华熙生物：业绩整体符合预期 功能性护肤品表现持续亮眼",
            "features": {
                "keywords": [
                    "华熙生物",
                    "功能性护肤品",
                    "业绩",
                    "Q3"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华熙生物：业绩整体符合预期 功能性护肤品表现持续亮眼",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "华熙生物Q3营收增长65.69%至10.76亿元",
            "features": {
                "keywords": [
                    "华熙生物",
                    "Q3",
                    "营收增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华熙生物Q3营收增长65.69%至10.76亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "国盛证券给予华熙生物买入评级，战略性投入持续加码，巩固医美护肤品牌力",
            "features": {
                "keywords": [
                    "国盛证券",
                    "华熙生物",
                    "买入评级",
                    "医美",
                    "护肤品牌"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美",
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "国盛证券给予华熙生物买入评级，战略性投入持续加码，巩固医美护肤品牌力",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "和讯SGI公司|华熙生物股价腰折，“玻尿酸之王”称号正摇摇欲坠？",
            "features": {
                "keywords": [
                    "华熙生物",
                    "股价腰折",
                    "玻尿酸之王"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "和讯SGI公司|华熙生物股价腰折，“玻尿酸之王”称号正摇摇欲坠？",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "安信证券：给予华熙生物买入评级，目标价位204.0元",
            "features": {
                "keywords": [
                    "安信证券",
                    "华熙生物",
                    "买入评级",
                    "目标价位"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "安信证券：给予华熙生物买入评级，目标价位204.0元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "华熙生物2021年三季报点评：C端占比提升，持续新品孵化",
            "features": {
                "keywords": [
                    "华熙生物",
                    "三季报",
                    "C端",
                    "新品孵化"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华熙生物2021年三季报点评：C端占比提升，持续新品孵化",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "联合丽格携手华熙生物开启“医美正品承诺”行动 —— 不忘初心，健康变美",
            "features": {
                "keywords": [
                    "联合丽格",
                    "华熙生物",
                    "医美正品承诺"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "联合丽格携手华熙生物开启“医美正品承诺”行动 —— 不忘初心，健康变美",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "国金证券维持华熙生物买入评级：功能性护肤品持续增长，医美业务战略升级",
            "features": {
                "keywords": [
                    "国金证券",
                    "华熙生物",
                    "功能性护肤品",
                    "医美业务"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "消费品",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持华熙生物买入评级：功能性护肤品持续增长，医美业务战略升级",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]